36230-47-4

Upstream product

• 27673-48-9 5,8-dihydro-1-naphthol 
• 77-78-1 dimethyl sulfate 
• 2216-69-5 1-Methoxynaphthalene 
• 90-15-3 α-naphthol 
• 10075-63-5 1,5-dimethoxynaphthalene 

Downstream Products

• 104195-17-7 SDZ NVI-085 
• 847199-04-6 2,3-bis-(2-hydroxyethyl)-1-methoxybenzene 
• 1008-19-1 5-methoxy-1,2,3,4-tetrahydro-naphthalene 
• 1202362-62-6 toluene-4-sulfonic acid (2S,4aR,10aR)-9-methoxy-4-propyl-3,4,4a,5,10,10a-hexahydro-2H-naptho[2,3-b][1,4]oxazin-2-ylmethyl ester 
• 1202361-83-8 (2R,4aR,10aR)-9-methoxy-2-(3-phenyl-pyrazol-1-ylmethyl)-4-propyl-3,4,4a,5,10,10a-hexahydro-2H-naphtho[2,3-b][1,4]oxazine 
• 1202361-84-9 (2S,4aR,10aR)-9-methoxy-2-(3-phenyl-pyrazol-1-ylmethyl)-4-propyl-3,4,4a,5,10,10a-hexahydro-2H-naphtho[2,3-b][1,4]oxazine 
• 1202362-65-9 toluene-4-sulfonic acid (2R,4aR,10aR)-9-methoxy-4-propyl-3,4,4a,5,10,10a-hexahydro-2H-naptho[2,3-b][1,4]oxazin-2-ylmethyl ester 

Relevant academic research and scientific papers

Experimental and Theoretical Studies on the Aqueous Solvation and Reactivity of SmCl2 and Comparison with SmBr2 and SmI2

Water addition to Sm(II) has been shown to increase reactivity for both SmI2 and SmBr2. Previous work in our groups has demonstrated that this increase in reactivity can be attributed to coordination induced bond weakening enabling substrate reduction through proton-coupled electron transfer. The present work examines the interaction of water with samarium dichloride (SmCl2) and illustrates the importance of the Sm-X interaction and bond distance upon water addition critical for the reactivity of the reagent system. Born-Oppenheimer molecular dynamics simulations identify substantial variations among the reductants created in solution upon water addition to SmI2, SmBr2, and SmCl2 with the latter showing the least halide dissociation. This results in a lower water coordination number for SmCl2, creating a more powerful reducing system. As previously shown with the other SmX2-water systems, coordination-induced bond-weakening of the O-H bond of water bound to Sm(II) results in significant bond weakening. In the case of SmCl2, the bond weakening is estimated to be in the range of 83 to 88.5 kcal/mol.

Synthesis and SAR study of a novel series of dopamine receptor agonists

The synthesis of a novel series of dopamine receptor agonists are described as well as their in vitro potency and efficacy on dopamine D1 and D2 receptors. This series was designed from pergolide and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinolin-6-ol (PHBQ) and resulted in the synthesis of (2R,4aR,10aR)-2-methylsulfanylmethyl-4-propyl- 3,4,4a,5,10,10a-hexahydro-2H-naphtho[2,3-b][1,4]oxazin-9-ol (compound 27), which has a D1 and D2 receptor profile similar to that of the most recently approved drug for Parkinson's disease, rotigotine.

Hydroxide ion as electron source for photochemical Birch-type reduction and photodehalogenation

The photochemical Birch-type reduction of arenes and the photodehalogenation of haloarenes by a hydroxide ion that acted as an electron source occurred in 2-PrOH. The efficiency of these photoreactions was dependent on the nature of the substrate, the concentration of NaOH, and the solvent used. These photoreactions provide an environmentally friendly method for the reduction of aromatic rings and dehalogenation.

6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.

6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorde

6-SUBSTITUTED- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS

The present invention provides 6-substituted 2,3,4,5-tetrahydro-lH- benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R? N-R" R* where R6 is -(CrC3)alkyl-S-(C0-C3)alkyl-R10, -(C1-C3)alkyl-NR11R12, -(CrC3)alkyl-O- R 13. and other substituents are as defined in the specification.

6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS

The present invention provides 6-substituted 2,3,4,5-tetrahydro-lH- benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is -NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.

6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINE AS A 5-HT2c RECEPTOR AGONIST

The present invention provides a 7-chloro-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine of formula (I): or a pharmaceutically acceptable salt thereof, and its use as a selective 5-HT2c agonist for the treatment of 5-HTsub